Gassifol-AR Capsule SR

Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, thereby protecting the gastrointestinal mucosa from NSAID-induced irritation and ulceration. This combination is particularly beneficial in patients requiring long-term NSAID therapy who are at risk of developing gastric ulcers or dyspepsia.

Gassifol-AR Capsule SR is indicated for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other musculoskeletal disorders where inflammation and pain are prominent, alongside prevention and treatment of NSAID-associated gastric complications. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and symptom control.

Use of this medication should be under medical supervision, considering contraindications such as hypersensitivity to components, active peptic ulcer, or severe hepatic impairment. Monitoring for adverse effects, including gastrointestinal discomfort, renal function, and hypersensitivity reactions, is recommended during therapy.